Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$52.66 USD
+0.57 (1.09%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $52.64 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 41 - 60 ( 313 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2Q22 Results; AdCom and PDUFA Dates on the Horizon; Things Getting Real Exciting
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv''s PDUFA Extended on PK Data Fine-Tuning; Our Thesis Remains Unaltered
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Echo Measures Showcase Early Benefits of Aficamten on Cardiac Structure and Function at ASE
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Longer-Term Aficamten Data at ESC-HF Do Not Disappoint; Omecamtiv Continues to Strengthen Its Profile
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
1Q22 Results; Late Stage Execution Continues According to Plan
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Mavacamten Crosses the Finish Line; We are Confident Aficamten Is Next and Could Do Better; Target Increased to $75
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Cardiac Myosin Inhibitors Shine at ACC.22; Full REDWOOD-HCM Cohort 3 Results Impress
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2021 Results; Late Stage Execution Continues With Solid Strategy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
METEORIC-HF Fails; Omecamtiv''s Journey to Regulatory Approval Remains Unaltered, We Believe
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv Marches Steadily Toward Potential FDA Approval; PDUFA Set for November 30, 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Aficamten Expands Positive Safety and Efficacy to Harder-to-Treat oHCM Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Cardiac Pipeline Continues to Deliver Solid Deals Ahead of Key Milestones
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv Partners Up For Commercialization in Greater China; Target Upped to $69
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Aficamten Shifts to Higher Gear in oHCM With Breakthrough Therapy Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Mavacamten''s PDUFA Postponed as REMS Discussions Deepen; Aficamten Continues to Rise to Top
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
3Q21 Results; Major Execution Phase Underway Across Pipeline; Target Increased to $62
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Important Inflection Points Shortly for Differentiated Assets; Investor Day Takeaways
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Aficamten Reinforces Its Competitive Profile at HFSA; Omecamtiv Solidifies its NDA Sumbission
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2Q21 Results; Late Stage Pipeline Progresses Towards Value Drivers
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J